These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 19593085)

  • 41. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
    Cheng YC; Ueno NT
    Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
    Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allogeneic hematopoietic stem cell transplantation in the elderly.
    Shapira MY; Tsirigotis P; Resnick IB; Or R; Abdul-Hai A; Slavin S
    Crit Rev Oncol Hematol; 2007 Oct; 64(1):49-63. PubMed ID: 17303434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
    Johnston L
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
    Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
    J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
    Childs RW
    Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation.
    Tabbara IA; Ingram RM
    Exp Hematol; 2003 Jul; 31(7):559-66. PubMed ID: 12842701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
    Baron F; Sandmaier BM
    Leukemia; 2006 Oct; 20(10):1690-700. PubMed ID: 16871276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
    Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
    Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging drugs for acute graft-versus-host disease.
    Khaled Y; Reddy P; Krijanovski O
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
    Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
    Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
    Oyama Y; Traynor AE; Barr W; Burt RK
    Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S81-3. PubMed ID: 12931250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent progress in allogeneic stem cell transplantation.
    Mattsson J
    Curr Opin Mol Ther; 2008 Aug; 10(4):343-9. PubMed ID: 18683098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
    Goldstein SC; Porter DL
    Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of infections complicating allogeneic hematopoietic stem cell transplantation.
    Hiemenz JW
    Semin Hematol; 2009 Jul; 46(3):289-312. PubMed ID: 19549581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-cell depletion does not necessarily compromise donor stem cell engraftment in patients receiving reduced-intensity conditioning regimens.
    Craddock C; Grigg AP
    Bone Marrow Transplant; 2003 Jun; 31(12):1177; author reply 1179. PubMed ID: 12796800
    [No Abstract]   [Full Text] [Related]  

  • 60. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning.
    Baron F; Storb R
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):799-819. PubMed ID: 16258490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.